Skip to main
LUNG
LUNG logo

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 0%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Pulmonx Corp is poised for growth with anticipated revenue acceleration starting in 2026, supported by ongoing international expansion and a disciplined approach to investment in revenue-generating activities. The company has reaffirmed a strong gross margin target of 74% for 2025 while tightening operating expense expectations, suggesting effective cost management. Future value prospects are closely tied to successful clinical trials and the integration of AI-driven technologies, which are expected to enhance patient identification and facilitate broader market adoption of its innovative treatments for severe emphysema.

Bears say

Pulmonx Corp reported preliminary Q3 revenue of approximately $21.5 million, reflecting a sequential decline from Q2's revenue of $23.9 million, highlighting a concerning slowdown in revenue generation. This decline prompted a revision of the company's annual revenue guidance to a range of $90 million to $92 million, indicating a loss of momentum that may further increase execution risks associated with its product models. Additionally, the company's gross margins fell from 72% in Q2 due to pressures from product mix and conversion timing, which raises further concerns about overall profitability moving forward.

Pulmonx (LUNG) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 0% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 7 analysts, Pulmonx (LUNG) has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.